Modality
mRNA
MOA
FXIai
Target
PD-1
Pathway
Epigenetic
NMOSD
Development Pipeline
Preclinical
~Aug 2020
→ ~Nov 2021
Phase 1
Feb 2022
→ May 2029
Phase 1Current
NCT08628706
1,721 pts·NMOSD
2022-02→2029-05·Active
NCT07176679
2,288 pts·NMOSD
2024-09→2027-03·Not yet recruiting
4,009 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-03-1611mo awayInterim· NMOSD
2029-05-053.1y awayInterim· NMOSD
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2
P1
Active
P1
Not yet…
Catalysts
Interim
2027-03-16 · 11mo away
NMOSD
Interim
2029-05-05 · 3.1y away
NMOSD
ActiveNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08628706 | Phase 1 | NMOSD | Active | 1721 | PFS |
| NCT07176679 | Phase 1 | NMOSD | Not yet recr... | 2288 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Pexanesiran | United Therapeutics | Phase 1 | BCMA |